FibroBiologics, Inc. Common Stock / "Long-term" | Tables in SEC filings

FBLG FibroBiologics, Inc. Common Stock

Quarterly report

	September 30, 2024		December 31, 2023
		(Unaudited)
Assets
Current assets
Cash and cash equivalents	$	7,827	$	9,163
Prepaid expenses		353		36
Other current assets		18		16
Total current assets		8,198		9,215
Property and equipment, net		772		797
Operating lease right-of-use asset, net		1,499		1,809
Total assets	$	10,469	$	11,821

Liabilities and stockholders’ equity
Current liabilities
Accounts payable and accrued expenses	$	1,179	$	1,444
Parent company payable		—		141
Operating lease liability, short-term		392		362
GEM commitment fee payable		1,863		—
Forward contract liability		241		—
Liability instrument		—		7,236
Warrant liability		2,887		—
Short-term note payable		115		—
Total current liabilities		6,677		9,183
Operating lease liability, long-term		1,055		1,385
Total liabilities		7,732		10,568

Stockholders’ equity
Preferred Stock, $0.00001 par value; 10,000,000 shares and 20,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively		—		—
Preferred Stock, $0.00001 par value; 0 shares and 8,750,000 Series A Preferred shares authorized as of September 30, 2024 and December 31, 2023, respectively; 0 shares and 8,750,000 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively		—		—
Preferred Stock, $0.00001 par value; 0 shares and 5,000,000 Series B Preferred shares authorized as of September 30, 2024 and December 31, 2023, respectively; 0 shares and 4,171,445 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively		—		—
Preferred Stock, $0.00001 par value; 0 shares and 5,000,000 Series B-1 Preferred shares authorized as of September 30, 2024 and December 31, 2023, respectively; 0 shares and 89,781 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively		—		—
Preferred Stock, $0.00001 par value; 2,500 Series C Preferred shares authorized; 2,500 shares and 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively		—		—
Preferred Stock, value		—		—
Non-voting Common Stock, $0.00001 par value; 0 shares and 30,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 0 shares and 28,230,842 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively		—		1
Voting Common Stock, $0.00001 par value; 100,000,000 shares authorized; 33,917,961 shares and 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively		—		—
Common Stock, value		—		—
Additional paid-in capital		35,156		25,609
Accumulated deficit		(32,419)		(24,357)
Total stockholders’ equity		2,737		1,253
Total liabilities and stockholders’ equity	$	10,469	$	11,821

Position	Annual Retainer
Board:
Members (other than chair)	$	35,000
Audit Committee:
Members (other than chair)	$	8,000
Retainer for chair	$	10,000
Compensation Committee:
Members (other than chair)	$	6,000
Retainer for chair	$	10,000
Nominating Committee:
Members (other than chair)	$	5,000
Retainer for chair	$	10,000

Position	Annual Retainer
Board:
Members (other than chair)	$	35,000
Audit Committee:
Members (other than chair)	$	8,000
Retainer for chair	$	10,000
Compensation Committee:
Members (other than chair)	$	6,000
Retainer for chair	$	10,000
Nominating Committee:
Members (other than chair)	$	5,000
Retainer for chair	$	10,000

Position	Annual Retainer
Board of Directors:
Members (other than chair)	$	35,000
Audit Committee:
Members (other than chair)	$	8,000
Retainer for chair	$	10,000
Compensation Committee:
Members (other than chair)	$	6,000
Retainer for chair	$	10,000
Governance and Nominating Committee:
Members (other than chair)	$	5,000
Retainer for chair	$	10,000

Table search / FibroBiologics, Inc. Common Stock / "Long-term"

13 results

Top filers

Top filing types

Recent filing years